Zasocitinib: all 26 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)Not yet recruitingNCT07871721Phase 3
• A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNot yet recruitingNCT07752108Phase 3
• A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's DiseaseRecruitingNCT07403968Phase 2
• Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisRecruitingNCT07286058Phase 3
• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisRecruitingNCT07250802Phase 3
• A Study of Zasocitinib in Adults With Hidradenitis SuppurativaRecruitingNCT07244263Phase 2
• A Study of Zasocitinib in Adults With Nonsegmental VitiligoRecruitingNCT07108283Phase 2
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)RecruitingNCT06764615Phase 2
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesRecruitingNCT06671483Phase 3
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06233461Phase 2
• A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic ArthritisCompletedNCT05153148Phase 2Results posted
• Study of NDI-034858 in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04999839Phase 2Results posted
• A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisCompletedNCT06973291Phase 3
• A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy AdultsCompletedNCT06793943Phase 1
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesActive, not recruitingNCT06671496Phase 3
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisActive, not recruitingNCT06550076Phase 3
• A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT06323356Phase 3
• A Study of the Interaction of Other Drugs With TAK-279 in Healthy AdultsCompletedNCT06290050Phase 1
• A Study of TAK-279 in Healthy Adults on the Effect on ECG MeasurementsCompletedNCT06258265Phase 1
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06254950Phase 2
• A Study of TAK-279 in Healthy Chinese AdultsCompletedNCT06111547Phase 1
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedNCT06108544Phase 3
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedNCT06088043Phase 3
• A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy AdultsCompletedNCT05995249Phase 1
• A Study of TAK-279 in Adults With or Without Kidney ProblemsCompletedNCT05992155Phase 1
• A Study of TAK-279 in Adults With or Without Liver DamageCompletedNCT05976321Phase 1

← Zasocitinib overview